Insmed (INSM)
Insmed (INSM) Stock Price, Analysis & Data
| Bid | 124.07 |
| Market Cap | 28.84B |
| Revenue (ttm) | 1.14B |
| Net Income (ttm) | -875.31M |
| Beta | 0.79 |
| EPS (ttm) | -4.12 |
| PE Ratio (ttm) | n/a |
| Forward PE | 155.05 |
| P/B (ttm) | 38.05 |
| P/S (ttm) | 25.35 |
| Earnings Date | Oct 29, 2026 |
| Ask | 159.6 |
| Volume | 28,575 |
| Avg. Volume (20D) | 3,790,408 |
| Open | 132.31 |
| Previous Close | 132.57 |
| Day's Range | 130.80 - 132.66 |
| 52-Week Range | 90.39 - 212.75 |
| Analyst | Strong Buy |
| Price Target | 197.5 (49.56%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also de...
Financial Performance
In 2025, Insmed's revenue was 606.42M, an increase of 66.73% compared to the previous year's 363.71M. Earnings were -1.28B, an increase of 39.73%.
Financial StatementsAnalyst Forecast
According to 22 analyst ratings, the average rating for INSM stock is "Strong Buy". The 12-month stock price forecast is 197.5, which is upside of 49.56% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
